Summary
Vertex Pharmaceuticals Inc. reported a significant increase in total revenues for the first quarter of 2016, reaching $398.1 million, a substantial jump from $138.5 million in the prior year period. This growth was primarily driven by the strong performance of ORKAMBI, which was approved in mid-2015, and continued growth in KALYDECO sales. Despite the revenue surge, the company reported a net loss attributable to Vertex of $41.6 million for the quarter, an improvement from the $198.6 million net loss in Q1 2015. The company's research and development expenses increased to $255.9 million, reflecting ongoing investment in its pipeline, particularly in cystic fibrosis therapies. Vertex's balance sheet remains robust, with $1.03 billion in cash, cash equivalents, and marketable securities as of March 31, 2016. Management expects current liquidity and anticipated cash flows from product sales to be sufficient for at least the next twelve months. The company continues to focus on advancing its key drug candidates, especially in cystic fibrosis, and managing its operational expenses while investing in future growth opportunities.
Financial Highlights
49 data points| Revenue | $398.08M |
| Cost of Revenue | $49.79M |
| Gross Profit | $348.29M |
| R&D Expenses | $255.86M |
| SG&A Expenses | $105.21M |
| Operating Expenses | $412.41M |
| Operating Income | -$14.33M |
| Net Income | -$41.63M |
| EPS (Basic) | $-0.17 |
| EPS (Diluted) | $-0.17 |
| Shares Outstanding (Basic) | 243.83M |
| Shares Outstanding (Diluted) | 243.83M |
Key Highlights
- 1Total revenues dramatically increased by 187% to $398.1 million in Q1 2016 from $138.5 million in Q1 2015, primarily due to ORKAMBI and KALYDECO product revenues.
- 2Net loss attributable to Vertex narrowed significantly to $41.6 million ($0.17 per share) in Q1 2016, a substantial improvement from a net loss of $198.6 million ($0.83 per share) in Q1 2015.
- 3Product revenues, driven by ORKAMBI ($223.1 million) and KALYDECO ($170.5 million), grew 201% to $394.4 million.
- 4Research and development expenses rose by 19% to $255.9 million, indicating continued investment in pipeline development, especially for cystic fibrosis.
- 5Sales, general and administrative expenses increased by 23% to $105.2 million, reflecting investment in commercial support for ORKAMBI in international markets.
- 6The company maintained a strong liquidity position with $1.03 billion in cash, cash equivalents, and marketable securities as of March 31, 2016.
- 7Vertex filed a supplemental New Drug Application (sNDA) for ORKAMBI for younger CF patients (6-11 years old) and is advancing multiple clinical trials for its next-generation CFTR corrector compounds.